SCHEMBL26585989

SCHEMBL26585989

Cc1ccnc(Oc2ccc(N)cc2F)n1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 7/20 0.50
▸ FEN1 P39748 6/20 0.50
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ FGFR2 P21802 1/20 0.42
▸ FGFR4 P22455 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ MAPK14 Q16539 1/20 0.40
▸ TRPA1 O75762 5/20 0.39
▸ ROCK2 O75116 2/20 0.37
▸ AXL P30530 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ CASP6 P55212 1/20 0.36
▸ GRM4 Q14833 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22676393 0.85 ALOX5AP (0.46) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL24773521 0.82 ALOX5AP (0.45) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL30306048 0.82 ALOX5AP (0.45) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL25714089 0.82 ALOX5AP (0.45) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL30680165 0.80 ALOX5AP (0.54) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL24772742 0.80 CYP3A4 (0.49) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL22677156 0.80 ALOX5AP (0.43) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL30717991 0.79 ALOX5AP (0.50) ALOX5APFEN1CYP3A4CYP2D6FGFR1
SCHEMBL17241848 0.78 ALOX5AP (0.43) ALOX5APFEN1MAPK14
SCHEMBL1643639 0.78 GRM2 (0.42) MAPK14TRPA1ROCK2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466897-A Highly selective FGFR2 inhibitors 深圳福沃药业有限公司 2024-01-30 — — CN disclosed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback